modelTerbinafine

Diagram of Terbinafine

Extends from Pharmacolibrary.Drugs.ATC.D.D01BA02.

Information

name:Terbinafine
ATC code:D01BA02
route:oral
compartments:2
dosage:250mg
volume of distribution:780L
clearance:4.6L/h
other parameters in model implementation

Terbinafine is an allylamine antifungal agent primarily used to treat fungal infections of the skin and nails, including onychomycosis and tinea infections. It is approved and widely used today for both oral and topical treatment of dermatophytic infections.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult volunteers (oral administration).

References

  1. Scher, RK (1999). Onychomycosis: therapeutic update. Journal of the American Academy of Dermatology 40(6 Pt 2) S21–S26. DOI:10.1016/s0190-9622(99)70397-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/10367912

  2. Gupta, AK, et al., & Cooper, EA (2003). The efficacy and safety of terbinafine in children. Journal of the European Academy of Dermatology and Venereology : JEADV 17(6) 627–640. DOI:10.1046/j.1468-3083.2003.00691.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/14761128

  3. Gupta, AK, et al., & Cooper, EA (2024). Efinaconazole 10% solution: a comprehensive review of its use in the treatment of onychomycosis. Expert opinion on pharmacotherapy 25(15) 1983–1998. DOI:10.1080/14656566.2024.2416924 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39394930

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)